Navigating Cyberbiosecurity Risks in Artificial Pancreas Systems: A Clinical Governance Challenge

      Automated insulin delivery (AID) and artificial pancreas (AP) systems have become pivotal in managing conditions like type 1 diabetes, transitioning from research to widespread clinical use. These systems integrate continuous glucose sensing, control algorithms, software, and insulin delivery hardware to automate a life-sustaining therapy in real time. While commercially available systems undergo rigorous regulatory approval, a growing phenomenon sees patients adopting "do-it-yourself" (DIY) artificial pancreas systems that operate outside conventional regulatory and institutional control structures. This introduces a complex landscape of safety, ethical, and cyberbiosecurity challenges that healthcare professionals must navigate (Source: Austin James et al., 2024).

      The core issue lies in how routine clinical practices intersect with cyberbiosecurity risks across both regulated and DIY AID systems. When medical devices are reconfigured into bespoke systems, and patients assume roles typically handled by manufacturers without mandated governance, the entire ecosystem of stakeholders faces legal and clinical uncertainty. This article delves into the intricacies of these systems, the risks they pose, and the governance frameworks required to ensure patient safety.

The Landscape of Artificial Pancreas Systems

      Artificial Pancreas systems are essentially cyber-physical medical technologies critical for safety. They continuously monitor glucose levels and adjust insulin delivery based on sophisticated algorithms. These systems have shown significant effectiveness in improving glycemic outcomes for individuals with type 1 diabetes. However, as their adoption expands, clinicians are increasingly managing the operational intricacies of software-driven systems embedded within daily care workflows. This complexity is particularly pronounced with the rise of DIY systems.

      Regulated AID systems follow formal medical device regulatory frameworks, ensuring safety, effectiveness, and post-market surveillance. These commercial solutions combine approved glucose monitors, insulin pumps, and proprietary algorithms, backed by clinical trials. They offer clinicians standardized documentation, manufacturer training, defined update pathways, and clear liability boundaries. Despite these safeguards, regulated systems still present considerable handling challenges in clinical environments. Issues like clinician familiarity, alarm fatigue, integration with hospital workflows, and decision-making during acute illness remain significant. Even regulated systems require active clinical governance and contingency planning, rather than being "set-and-forget" technologies.

The Rise of DIY and Non-Regulated Systems

      In parallel with regulated solutions, patient-led innovation has fostered DIY and open-source artificial pancreas systems. These often combine off-the-shelf continuous glucose monitors and insulin pumps with community-developed algorithms, smartphone apps, and cloud services, supported by informal peer networks. While observational studies suggest comparable glycemic outcomes in self-selected populations, these systems operate without formal regulatory approval or manufacturer backing. For instance, the source mentions Tidepool Loop becoming the first open-source automated insulin delivery mobile application to receive formal recognition as safe and effective in 2023, which complicates the traditional regulated vs. DIY divide.

      From a clinical perspective, DIY systems present unique governance challenges. Clinicians may observe improved glycemic stability in patients using DIY setups but lack access to validated documentation, reliable update mechanisms, or audit trails for software integrity and algorithmic logic. This creates uncertainty regarding legal responsibility, ethical obligations, and whether engaging with DIY systems constitutes endorsement or simply harm reduction.

The "User-as-Accidental-Threat" Paradox

      A critical distinction between regulated and DIY systems lies in governance and authority. In regulated devices, security governance is managed by manufacturers. DIY systems, however, blur the lines between patient, developer, and operator. The patient often assumes significant technical authority while clinical responsibility for outcomes largely remains with healthcare professionals. This divergence creates what is termed the "user-as-accidental-threat" paradox.

      In DIY contexts, all security functions are concentrated within the patient-user. This makes them the single point of security failure, often unintentionally. Well-intentioned actions, such as misconfigured updates, algorithm tweaks, or delayed security patches, can become primary threat vectors to system integrity and availability. This highlights that cyberbiosecurity considerations, including software provenance (where the software came from), trust, and configuration control, become far more critical in DIY settings, even when there is no malicious intent. Ensuring the integrity and reliability of such systems is paramount, a challenge that robust AI and IoT solutions, such as those that provide on-premise processing and data control, are designed to address. ARSA Technology, for example, develops AI Box Series for edge AI deployments, which process data locally, enhancing security and minimizing latency, a critical consideration for health-related devices.

Cyberbiosecurity: A Governance Challenge for Patient Safety

      Cyberbiosecurity risks in artificial pancreas systems fundamentally stem from mismatches between clinical responsibility and technical authority. This is particularly evident in DIY contexts where software provenance is often diffuse, meaning its origin and maintenance are unclear. Analyzing national position statements from countries like Australia, Canada, and the UK reveals varied institutional responses, often attempting to manage risk without officially endorsing unregulated technology.

      Regulatory frameworks can, perhaps unintentionally, encourage DIY adoption if they create perceived barriers to access for advanced, personalized care. This further exacerbates the mismatch in responsibility and authority. The paper suggests that grounding cyberbiosecurity analysis in everyday clinical workflows is essential, framing it not just as a technical problem but as a significant governance challenge for patient safety.

Towards Minimal Clinical Cyber-Safety Handling

      To address these complex issues, a proposed minimal clinical cyber-safety handling bundle focuses on harm containment, clear governance, and defensible decision-making, rather than solely optimizing device performance. Key clinical handling themes include:

• Eligibility for Use: Establishing clear criteria for who can safely use these systems.
• Override Authority: Defining when and how clinical staff can override system decisions.
• Alarm Management: Developing strategies to manage alert fatigue and ensure critical alarms are heeded.
• Data Validation: Implementing methods to verify the accuracy and integrity of data generated by the systems.
• Transitions of Care: Ensuring seamless and secure information transfer when patients move between different care settings.

      These aspects relate to attacks on integrity, availability, and authorization, all of which are relevant to patient safety. The goal is to establish clear protocols and guidelines that support healthcare professionals in managing patients with both regulated and DIY systems, prioritizing patient well-being while acknowledging technological realities. For mission-critical systems where data integrity and security are non-negotiable, solutions like ARSA's Face Recognition & Liveness SDK offer on-premise deployment for full data control and compliance. ARSA has been experienced since 2018 in developing robust AI and IoT solutions that meet the demands of regulated environments.

Critical Research Gaps and Future Directions

      The academic paper identifies several critical gaps in current research:

• Failure Modes: A comprehensive understanding of how both regulated and DIY systems can fail, and the specific cyberbiosecurity implications of these failures.
• Incident Reporting: Lack of standardized mechanisms for reporting incidents related to DIY systems, which hinders learning and risk mitigation.
• DIY System Governance: The absence of formal governance structures for community-developed software, leaving clinicians in a legally ambiguous position.

      Further discussion and research are vital to develop robust frameworks that ensure patient safety without stifling innovation. This requires collaboration between healthcare professionals, regulators, technology developers, and patient communities to create an environment where the benefits of advanced AI and IoT in healthcare can be fully realized, securely and ethically.

      For enterprises and governments seeking to deploy secure, reliable, and compliant AI and IoT solutions in safety-critical sectors, understanding these governance challenges is paramount. Explore ARSA Technology's range of AI and IoT solutions and how they can be tailored to meet stringent security and operational demands by requesting a free consultation.

      Source: Austin James, Xavier-Lewis Palmer, Lucas Potter, & Celisha Oscar. (2024). Artificial Pancreas Implantables – How Healthcare Professionals May Deal With DIY Bio Cases. arXiv preprint arXiv:2605.20208. Retrieved from https://arxiv.org/abs/2605.20208